NCT04622826 is a Phase 2 clinical trial of immune plasma in Covid-19 Pneumonia, sponsored by Azienda USL Toscana Nord Ovest.

Who is sponsoring NCT04622826?

NCT04622826 is sponsored by Azienda USL Toscana Nord Ovest.

What drugs are being tested in NCT04622826?

Interventions in NCT04622826: immune plasma.

What condition does NCT04622826 study?

NCT04622826 studies Covid-19 Pneumonia.

Is NCT04622826 still recruiting?

NCT04622826 is currently status unknown. Last updated 10 November 2020.

Last reviewed 2020-11-10 · How we verify

NCT04622826

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

plasmApuane CoV-2 : Efficacy and Safety of Immune Covid-19 Plasma in Covid-19 Pneumonia in Non ITU Patients

Status unknown Phase 2 Last updated 10 November 2020

What this trial tests

Phase 2 trial testing immune plasma in Covid-19 Pneumonia in 50 participants. Status unknown.

Timeline

15 May 2020

Primary endpoint
31 December 2020

31 December 2020

Quick facts

Lead sponsor	Azienda USL Toscana Nord Ovest
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	sequential
Masking	none
Primary purpose	prevention
Enrollment	50
Start date	15 May 2020
Primary completion	31 December 2020
Estimated completion	31 December 2020
Sites	1 location across Italy

Drugs / interventions tested

immune plasma — full drug profile →

Conditions studied

Covid-19 Pneumonia — all drugs for Covid-19 Pneumonia →

Sponsor

Azienda USL Toscana Nord Ovest — full company profile →

Who can join

18 and older, any sex, with Covid-19 Pneumonia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Aim of the study is to verify the efficacy and safety of convalescent hyperimmune plasma infusion in hospitalized covid-19 patients non in ITU with pneumonia and respiratory symptoms within seven days from the beginning of symptoms. Efficacy is evaluated by the number of patients who will improve their clinical condition and will not be admitted to ITU. .Safety is considered in relation to adverse reactions to plasma infusion.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
Piechotta V, Iannizzi C, Chai KL, Valk SJ, et al · · 2021 · cited 106× · PMID 34013969 · DOI 10.1002/14651858.cd013600.pub4
Convalescent plasma for people with COVID-19: a living systematic review.
Iannizzi C, Chai KL, Piechotta V, Valk SJ, et al · · 2023 · cited 24× · PMID 36734509 · DOI 10.1002/14651858.cd013600.pub5
Convalescent plasma for people with COVID-19: a living systematic review.
Iannizzi C, Chai KL, Piechotta V, Valk SJ, et al · · 2023 · cited 21× · PMID 37162745 · DOI 10.1002/14651858.cd013600.pub6
Convalescent plasma (hyperimmune immunoglobulin) for COVID-19 management: An update.
Chavda VP, Bezbaruah R, Dolia S, Shah N, et al · · 2023 · cited 10× · PMID 36741339 · DOI 10.1016/j.procbio.2023.01.018
Drugs and convalescent plasma therapy for COVID-19: a survey of the interventional clinical studies in Italy after 1 year of pandemic.
Puopolo M, Morciano C, Buoncervello M, De Nuccio C, et al · · 2022 · PMID 35733167 · DOI 10.1186/s13063-022-06474-8

Verify or expand the search:

Other Azienda USL Toscana Nord Ovest trials

Trials by the same sponsor.

NCT07386314 — Motor and Cognitive Telerehabilitation for Acquired Brain Injury · NA · not yet recruiting
NCT06256666 — Objective Measurement of Pain in Individuals With Cognitive Deterioration Utilizing Electroencephalography · completed
NCT04231058 — Non-pharmacological Treatment of Dyspnea in Chronic Obstructive Pulmonary Disease (COPD) · NA · suspended
NCT06176677 — Use of a Low-cost Video Laryngoscope on Manikin · completed
NCT05584904 — A Single Dry EEG Electrode Allows to Estimate of the Level of Anesthesia During Colonoscopy Sedation. · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04622826 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Azienda USL Toscana Nord Ovest
Last refreshed: 10 November 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04622826.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing